SCHEMBL5264786

SCHEMBL5264786

COc1cc(OC)c(NC(=O)c2ccc(Oc3cc4c(cc3C)OCC[Si]4(C)C)o2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 2/20 0.47
FPR1 P21462 1/20 0.47
GPR183 P32249 1/20 0.47
GPR119 Q8TDV5 1/20 0.47
S1PR4 O95977 7/20 0.37
S1PR2 O95136 3/20 0.37
ADORA3 P0DMS8 2/20 0.37
DRD1 P21728 2/20 0.37
HTR2A P28223 2/20 0.37
OPRM1 P35372 2/20 0.37
CACNA1F O60840 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM1 P11229 1/20 0.37
CYP2C9 P11712 1/20 0.37
DRD4 P21917 1/20 0.37
SLC6A2 P23975 1/20 0.37
HRH2 P25021 1/20 0.37
TACR1 P25103 1/20 0.37
PTAFR P25105 1/20 0.37
HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264487 0.92 S1PR4 (0.42) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5266538 0.90 GNRHR (0.51) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5264580 0.87 GNRHR (0.49) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5264506 0.86 GNRHR (0.51) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5269136 0.86 GNRHR (0.47) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5265545 0.85 GNRHR (0.49) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5269013 0.85 GNRHR (0.45) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5264689 0.85 GNRHR (0.47) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5264948 0.84 GNRHR (0.47) GNRHRFPR1GPR183GPR119S1PR4
SCHEMBL5264010 0.84 GNRHR (0.47) GNRHRFPR1GPR183GPR119S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648906-B1 ORGANOSILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-10-03 EP claimed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 US claimed
EP-1648906-B1 ORGANOSILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 US disclosed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111967-A1 Organosilicon compounds and their use CYP2B6, UGT1A6, CYP2D6 GNRHR 2847/4885FPR1 509/4885GPR183 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.